The goal for the multiyear partnership is to make genetic analysis a routine part of patient care.
While it’s remarkable that we can actually sequence entire genomes today, the process remains relatively expensive.
Today, the storied venture firm funded Spiral Medicine, a company that processes genetic information for the purposes of clinical medicine and research.
Is there more to your bacteria then meets the eye?
Bill Ericson doesn’t see much cause for pessimism about the dawning Genomic Age. The Mohr Davidow Ventures partner, who’s helped resuscitate the firm’s life-science practice since he came aboard in 2000, believes the widespread dissemination of genetic information will be a virtually unalloyed good, opening up a wealth of opportunities for more effective medicine, lower healthcare costs and individual empowerment — not to mention investment opportunities for those prescient enough to seize them. (See here and here for my own take on the subject.)